Country: United States
Language: English
Source: NLM (National Library of Medicine)
ECHOTHIOPHATE IODIDE (UNII: BA9QH3P00T) (ECHOTHIOPHATE - UNII:0F350BVT6S)
Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.
ECHOTHIOPHATE IODIDE
ECHOTHIOPHATE IODIDE 6.25 mg in 5 mL
PRESCRIPTION DRUG
Echothiophate iodide for ophthalmic solution is indicated for the reduction of elevated IOP. Concomitant esotropias with a significant accommodative component. - Active uveal inflammation. - Most cases of angle-closure glaucoma without iridectomy, due to the possibility of increasing angle block. - Hypersensitivity to the active or inactive ingredients.
Each package contains sterile echothiophate iodide for ophthalmic solution, sterile diluent, and dropper for dispensing 5 mL eyedrops. White amorphous deposit on bottle walls. Aluminum crimp seal is green. Prior to reconstitution: Store under refrigeration (2° to 8° C). After reconstitution: Store at room temperature (approximately 25° C). Do not refrigerate. Discard any unused solution after 4 weeks.
New Drug Application
PHOSPHOLINE IODIDE OPHTHALMIC- ECHOTHIOPHATE IODIDE WYETH PHARMACEUTICALS LLC, A SUBSIDIARY OF PFIZER INC. ---------- PHOSPHOLINE IODIDE (ECHOTHIOPHATE IODIDE FOR OPHTHALMIC SOLUTION) RX ONLY DESCRIPTION Chemical name: (2-mercaptoethyl) trimethylammonium iodide O,O-diethyl phosphorothioate Structural formula C H INO PS M.W. 383.23 Echothiophate iodide for ophthalmic solution occurs as a white, crystalline, water- soluble, hygroscopic solid having a slight mercaptan-like odor. When freeze-dried in the presence of potassium acetate, the mixture appears as a white amorphous deposit on the walls of the bottle. Each package contains materials for dispensing 5 mL of eyedrops: (1) bottle containing sterile echothiophate iodide for ophthalmic solution 6.25 mg (0.125%) with 40 mg potassium acetate. Sodium hydroxide or acetic acid may have been incorporated to adjust pH during manufacturing; (2) a 5 mL bottle of sterile diluent containing chlorobutanol (chloral derivative), 0.55%; mannitol, 1.2%; boric acid, 0.06%; and sodium phosphate, 0.026%; (3) sterilized dropper. CLINICAL PHARMACOLOGY Echothiophate iodide for ophthalmic solution is a long-acting cholinesterase inhibitor for topical use which enhances the effect of endogenously liberated acetylcholine in iris, ciliary muscle, and other parasympathetically innervated structures of the eye. It thereby causes miosis, increase in facility of outflow of aqueous humor, fall in intraocular pressure (IOP), and potentiation of accommodation. Echothiophate iodide for ophthalmic solution will depress both plasma and erythrocyte cholinesterase levels in most patients after a few weeks of eyedrop therapy. INDICATIONS AND USAGE REDUCTION OF ELEVATED IOP ® 9 23 3 REDUCTION OF ELEVATED IOP Echothiophate iodide for ophthalmic solution is indicated for the reduction of elevated IOP. ACCOMMODATIVE ESOTROPIA Concomitant esotropias with a significant accommodative component. CONTRAINDICATIONS 1. Active uveal inflammation. 2. Most cases of angle-closure glaucoma without iridectomy, due to Read the complete document